AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05412485 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Robotic assisted gait training
Description: Robotic assisted gait training is advanced technology used in the rehabilitation of neurological injuries and conditions like spinal cord injury, brain injury, stroke, multiple sclerosis, Parkinson's, cerebral palsy. It provides a repetitive task-specific motor training and modulates afferent input to spinal cord to generate rhythmic gait patterns that may be transformed to overground walking. The intensive repetitions of the rhythmic stepping movement during the training stimulates dependent plasticity and it may lead to brain reorganization. It facilitates cortical neural activities associated with motor control of walking.
Study NCT06306144 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerised Cognitive Stimulation
Description: Arm 2 :Patients will participate in a 6-week cognitive stimulation telerehabilitation intervention, that will consist of two 45-minute sessions per week. Each week they will participate in a 45-minute on-line session with a rehabilitation clinician and later in the week will complete 45 minutes of on-line exercises set by the rehabilitation clinician
Study NCT05049239 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical training
Description: Medium-high-intensity physical training 3 times a week, 60 min / time for 12 weeks, consisting of fitness, strength and mobility exercises with a target level of 60-90% of maximum heart rate. Two sessions per week take place in a group led by a physiotherapist and once a week the training consists of self-chosen training individually or in group.
Study NCT06306144 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Arm 3 : No specific care.
Study NCT05049239 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical training combined with cognitive support.
Description: Medium-high-intensity physical training 3 times a week, 60 min / time for 12 weeks, consisting of fitness, strength and mobility exercises with a target level of 60-90% of maximum heart rate. Two sessions per week take place in a group led by a physiotherapist and once a week the training consists of self-chosen training individually or in group.~The cognitive support consists of person centred individual occupational therapy with focus on daily time management skills and planning and organisation in daily life, i.e. make time for physical exercise. The number of session during the intervention period depend on the participants needs and is estimated to 4-6 sessions.
Study NCT04686643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGSAVI
Description: S-amlodipine, Valsartan, Indapamide
Study NCT04686643 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AGLS
Description: S-amlodipine, Valsartan
Study NCT06163547 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MMA embolization
Description: Middle meningeal artery embolization
Study NCT06163547 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: MMA embolization
Description: Middle meningeal artery embolization
Study NCT05406518 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychosocial intervention
Description: Psychosocial intervention based on the model of family therapy.
Study NCT06658249 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core Stabilization Exercises with Foot-Ankle Strengthening Program
Description: Core Stabilization Exercises and Foot-Ankle Strengthening Program with the frequency of 3 sets of 10 repetitions 3 times per week for a total duration of 6 weeks. Core Stabilization Exercises include : Double leg Abdominal Press, Single Leg Abdominal Press, Abdominal crunches, Side-lying Hip Abduction, Bridging Exercise, Wall Squats Exercise. Foot-Ankle Strengthening Program include : Step ups Exercise, Heel Raises in standing/sitting, Toe Raises in standing/sitting, Foot-Ankle isometrics with theraband, One leg balance with chair support. Pre and Post intervention values will be taken on 1st day and after 6 weeks. Simple Conventional treatment will also given that include Hot Pack and TENS for 10 minutes and Ultrasound for 5 minutes and Knee Isometric exercises with the frequency of 1 set of 10 repetitions with 5 sec hold with the ratio of 3 times per week for a total duration of 6 weeks.
Study NCT06658249 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Foot-Ankle Strengthening Program
Description: Foot-Ankle Strengthening Program along with common conventional treatment with the frequency of 3 sets of 10 repetition thrice per week for a total duration of 6 weeks. Core Stabilization Exercises include : Double leg Abdominal Press, Single Leg Abdominal Press, Abdominal crunches, Side-lying Hip Abduction, Bridging Exercise, Wall Squats Exercise. Foot-Ankle Strengthening Program include : Step ups Exercise, Heel Raises in standing/sitting, Toe Raises in standing/sitting, Foot-Ankle isometrics with theraband, One leg balance with chair support. Pre and Post intervention values will be taken on 1st day and after 6 weeks. Simple Conventional treatment will also given that include Hot Pack and TENS for 10 minutes and Ultrasound for 5 minutes and Knee Isometric exercises with the frequency of 1 set of 10 repetitions with 5 sec hold with the ratio of 3 times per week for a total duration of 6 weeks.
Study NCT06036810 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shared Medical Decision Tool
Description: standard of care
Study NCT06627881 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous aerobic kayak training program
Description: Sitting in a special chair on the Kayak Pro® Speed Stroke PRO ergometer. 5-minute warm-up and continuous training, for 30 minutes on the ergometer at a moderate to vigorous intensity, 5 days a week.
Study NCT06036810 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Engaging Patients in Decision Making
Description: standard of care
Study NCT06036810 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Literacy Spanish Language
Description: standard of care
Study NCT05312879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-147
Description: Tablets for oral administration.
Study NCT04816292 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Hot Snare Polypectomy
Description: Hot Snare Polypectomy with the use of electrocautery for the resection of polyps.
Study NCT04816292 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experimental: Cold Snare Polypectomy
Description: Cold Snare Polypectomy without the use of electrocautery for the resection of polyps.
Study NCT05947890 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MTBVAC
Description: The MTBVAC vaccine is a freeze-dried lyophilized pellet containing live attenuated strain MTBVAC01 derived from Mycobacterium tuberculosis (M.tb). Excipients include sucrose and sodium glutamate.
Study NCT05947890 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG
Description: The active substance in BCG vaccine is a freeze-dried powder containing live attenuated Mycobacterium bovis BCG, Danish strain 1331 and sodium glutamate as a stabilizer. The powder is white and crystalline and may be difficult to see due to the small amount contained in each vial.
Study NCT06011889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: treatment with etanercept in addition to NSAID treatment and/or classic Disease Modifying Antirheumatic Drugs
Study NCT06011889 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: treatment with placebo in addition to NSAID treatment and/or classic Disease Modifying Antirheumatic Drugs
Study NCT04867434 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RZL-012
Description: small synthetic molecule for submental fat reduction
Study NCT04867434 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06288789 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Social Frailty Index
Description: Social Frailty Index will be applied twice, one week apart.
Study NCT05029973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAIC
Description: hepatic arterial infusion (HAI) of oxaliplatin, fluorouracil/leucovorin (FOLFOX) treatment
Study NCT05029973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: 200mg IV d1,Q3W
Study NCT05029973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab Biosimilar
Description: 7.5mg/kg IV d1,Q3W
Study NCT05312879 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets for oral administration.
Study NCT06563895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acoramidis
Description: TTR stabilizer administered orally twice daily (BID)
Study NCT06563895 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Non-active control administered orally twice daily (BID)
Study NCT06642545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disitamab Vedotin
Description: Disitamab Vedotin 2.0mg/kg,intravenous infusion, every 2 weeks
Study NCT06642545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC148
Description: 20mg/kg, intravenous infusion, once every 2 weeks
Study NCT06642545 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albumin-bound Paclitaxone
Description: 125 mg/m2,intravenous infusion, D1-8, every 3 weeks
Study NCT06642545 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Toripalimab
Description: 240mg,intravenous infusion, once every 3 weeks
Study NCT06641232 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Comparison of anesthetic efficacy and safety between nerve block and infiltrative technique for mandibular posterior implant placement.
Description: The surgeon and his assistant will leave the operating room and the study investigator in charge of anesthetizing the patients (XA) will enter.~The anesthesia will be performed by an investigator other than the surgeon performing the procedure. The patient will be assigned to a treatment group; patients in the control group will undergo vestibular and lingual infiltration, while the experimental group will undergo inferior dental nerve block together with buccal nerve block.
Study NCT06641232 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Comparison of anesthetic efficacy and safety between nerve block and infiltrative technique for mandibular posterior implant placement.
Description: The surgeon and his assistant will leave the operating room and the study investigator in charge of anesthetizing the patients (XA) will enter.~The anesthesia will be performed by an investigator other than the surgeon performing the procedure. The patient will be assigned to a treatment group; patients in the control group will undergo vestibular and lingual infiltration, while the experimental group will undergo inferior dental nerve block together with buccal nerve block.
Study NCT05309629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL1706
Description: Intravenous infusions of QL1706 5mg/kg on Day 1 of every 21-day cycle.
Study NCT05309629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin intravenous infusion to achieve an initial target AUC of 5 mg/mL/min was administered on Day 1 of each 21-day cycle for 4-6 cycles.
Study NCT05309629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide intravenous infusion was administered at a dose of 100 mg/m\^2 on Days 1, 2, and 3 of each 21-day cycle for 4-6 cycles.
Study NCT06431347 — intervention group
Intervention type: BEHAVIORAL
Intervention: Social Determinants of Health Questionnaire
Description: Participants will also complete a questionnaire about financial barriers to care within the past year, including income bracket and difficulty affording cost-of-living or medical expenses.
Study NCT04782687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: oral drug that comes in 20 mg tablets
Study NCT04782687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Oral
Description: Dexamethasone 40 mg on Days 1, 8, 15, 22 of each cycle. However, those >75 years old may be administered a weekly dose of 20 mg dexamethasone.
Study NCT04782687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Patients will receive daratumumab subcutaneously (SC, or under the skin) as an injection. The recommended dosage of the SC formulation is 1,800 mg daratumumab and 30,000 units hyaluronidase administered SC into the abdomen over approximately 3 to 5 minutes according to recommended schedule.~Daratumumab 1800 mg subcutaneously once weekly in Cycles 1 and 2, every 2 weeks in cycles 3 to 6, and every 4 weeks thereafter.
Study NCT04782687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Patients will receive a 21-day supply of lenalidomide (15 mg) as oral capsules, as appropriate, for each 28-day treatment cycle
Study NCT05456113 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Urbal Activ Extra Strength CBD Body Strong Balm applied to region of forearm to be stimulated by iontophoresis machine
Study NCT06627881 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Endurance Circuit Program
Description: Sitting with feet flat on the floor and shoulder-width apart, in each session with a 5-minute warm-up, light intensity training with upper body strengthening, 5 days a week.
Study NCT06627881 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High intensity interval program with rope
Description: Sitting with feet flat on the floor and shoulder-width apart, in each session with a 5-minute warm-up, vigorous intensity undulating rope training using the interval method, 5 days a week.
Study NCT06627413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumateperone Capsule
Description: Lumateperone 42 mg capsule, oral administration
Study NCT05456113 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Cannabidiol
Description: Urbal Activ Extra Strength CBD Body Strong Balm applied to region of forearm to be stimulated by iontophoresis machine
Study NCT04804072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medication for opioid-use disorder (MOUD) for opioid-use disorder (OUD)
Description: MOUD for OUD
Study NCT06077708 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3K2
Description: Non-surgical periodontal treatment was applied to all individuals included in the study. 2 drops of the preparation containing 25 µg D3 \[1000 IU\] and 11.25 µg K2 in each drop were given per day to participants in the test group.
Study NCT04804072 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HIV testing
Description: HIV testing
Study NCT06077708 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: Non-surgical periodontal treatment was applied to all individuals included in the study and saline solution (0.9% NaCl) was given as placebo, 2 drops per day to particiapants in the control group.
Study NCT06498063 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucagon
Description: Glucagon infusion of 5 ng·kg-1·min-1 from 0-60 minutes and 10 ng·kg-1 ·min-1 from 60-120 minutes.
Study NCT06627413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumateperone LAI
Description: Lumateperone LAI X500-E2 IM injection
Study NCT06627413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumateperone LAI
Description: Lumateperone LAI X500-E3 IM injection
Study NCT06627413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumateperone LAI
Description: Lumateperone LAI X500-X2 IM injection
Study NCT06627413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumateperone LAI
Description: Lumateperone LAI X500-X5 IM injection
Study NCT06627413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumateperone LAI
Description: Lumateperone LAI (X500-E2 or X500-E3 or X500-X2 or X500-X5) IM injection
Study NCT05730816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Description: Intravenous infusion of magnesium sulfate prior to intraoperative chemotherapy with cisplatin.
Study NCT05730816 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Intravenous infusion of normal saline.
Study NCT05302661 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: re-education
Description: Contact patients by phone or wechat and guide them
Study NCT05246904 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fitting algorithm
Description: The best fitting algorithm will be selected by the audiologist (arm 1) or software.
Study NCT04891731 — intervention group
Intervention type: DRUG
Intervention: AI or TAM
Description: This is an observational study, the researcher will describe the ratio of E2 control between leuprorelin plus TAM or leuprorelin plus AIs patients based on the actual clinical use.
Study NCT06138288 — intervention group
Intervention type: BEHAVIORAL
Intervention: acupressure
Description: The acupressure points to be used in the research are located on the inner side of the lower leg, 4 fingers above the ankle and on the spleen meridian behind the tibia (SP6), which was previously effective in reducing pain, and located three fingers above the wrist (in the middle of the 2nd metacarpal bone, on the dorsum of the hand, adjacent The points determined as P6 (located between the metacarpal bones) and LI4 located in the space between the thumb and index finger (between the 1st and 2nd metacarpal bones of the hand, in the middle of the 2nd metacarpal bone on the radial side) were applied by a certified researcher to women in the acupressure group. will be done
Study NCT06498063 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Glucagon
Description: Glucagon infusion of 5 ng·kg-1·min-1 from 0-60 minutes and 10 ng·kg-1 ·min-1 from 60-120 minutes.
Study NCT06498063 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo (0.9% NaCl).
Study NCT06498063 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (0.9% NaCl).
Study NCT06498063 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucagon and exendin 9-39
Description: Glucagon (infusion of 5 ng·kg-1·min-1 from 0-60 minutes) and glucagon (infusion of 10 ng·kg-1 ·min-1 from 60-120 minutes) + a GLP-1R antagonist, exendin 9-39 (900 pmol·kg-1·min-1 from -30-120 minutes).
Study NCT06498063 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Glucagon and exendin 9-39
Description: Glucagon (infusion of 5 ng·kg-1·min-1 from 0-60 minutes) and glucagon (infusion of 10 ng·kg-1 ·min-1 from 60-120 minutes) + a GLP-1R antagonist, exendin 9-39 (900 pmol·kg-1·min-1 from -30-120 minutes).
Study NCT04804072 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: HIV testing
Description: HIV testing
Study NCT04804072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIV treatment for participants living with HIV not already in care
Description: HIV treatment for participants living with HIV not already in care
Study NCT06670586 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional in vitro fertilization
Description: Fertilization via conventional In Vitro Fertilization
Study NCT06670586 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intracytoplasmic sperm injection (ICSI)
Description: Fertilization via intracytoplasmic sperm injection
Study NCT06600802 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: A total of 3 blood samples (2 tubes of 9mL each) are added. The first sample will be taken at the inclusion visit, the 2nd at the end of the 2nd treatment cycle and the last at the end of Lu-PSMA treatment.
Study NCT06407401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 MG
Description: Patients randomized to the duloxetine arm will take duloxetine orally daily, with or without food, on a continuous dosing schedule.~Initial dose is 30 mg daily for 1 week, followed by 60 mg daily for a total of 6 months of treatment, followed by a taper off the medication of 30 mg daily for 1 additional week.
Study NCT06407401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide 40 mg
Description: Patients randomized to the furosemide arm will take furosemide 40 mg orally daily, on an empty stomach with plenty of liquid, on a continuous dosing schedule.
Study NCT06407401 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Booklet for healthy behaviors
Description: All patients will receive usual care, including a booklet focused on healthy behaviors, particularly physical exercise, to manage endocrine therapy side-effects.
Study NCT06407401 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Booklet for healthy behaviors
Description: All patients will receive usual care, including a booklet focused on healthy behaviors, particularly physical exercise, to manage endocrine therapy side-effects.
Study NCT04804072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PrEP for participants without HIV
Description: PrEP for participants without HIV
Study NCT04804072 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Testing and referral for vaccination or treatment for hepatitis A virus (HAV) and hepatitis B virus (HBV)
Description: Testing and referral for vaccination or treatment for HAV and HBV